Multicenter AIDS Cohort Study - Part B (Baltimore Center)

多中心艾滋病队列研究 - B 部分（巴尔的摩中心）

• 批准号: 8079217
• 负责人: Joseph B. Margolick
• 金额: $ 12.25万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8079217
• 关键词: Acquired Immunodeficiency Syndrome; Address; Adherence; Affect; Baltimore; Biological; Caucasians; Caucasoid Race; Characteristics; Chicago; Cohort Studies; Data; Disease Progression; Effectiveness; Enrollment; Ethnic Origin; Follow-Up Studies; Funding; Genetic; HIV-1; Hepatitis Viruses; Highly Active Antiretroviral Therapy; Host Defense; Host resistance; Human Herpesvirus 8; Immune response; Individual; Infection; Laboratories; Lead; Los Angeles; Measurement; Monitor; National Institute of Allergy and Infectious Disease; Natural History; Opportunistic Infections; Participant; Pathogenesis; Peripheral Blood Mononuclear Cell; Plasma; Play; Population; Preventive; Questionnaires; Race; Recruitment Activity; Request for Applications; Research; Research Design; Risk Factors; Role; Site; Specimen; T-Lymphocyte Subsets; Time; Vaccines; cohort; insight; member; pathogen; repository; response

DESCRIPTION (provided by applicant): The Study to Help the AIDS Research Effort (SHARE) was funded by NIAID and NCI in 1983 to study the natural history of infection with human immunodeficiency virus, type 1 (HIV). SHARE, along with similar sites in Chicago, Pittsburgh, and Los Angeles, forms the Multicenter AIDS Cohort Study (MACS). MACS participants, including 1447 enrolled in SHARE, have been followed semiannually since 1984 and have provided questionnaire data, physical exam data, laboratory data (including HIV serostatus and T-cell subset measurements), and a large repository of plasma, serum, cryopreserved peripheral blood mononuclear cells and other specimens. Evaluating and following the prevalent and incident cases of HIV-infection in SHARE and the MACS, has provided key insights into risk factors for infection with HIV-1, monitoring and mechanisms of progression of HIV infection once it is established, host defense against HIV, genetic factors affecting HIV pathogenesis, and use and efficacy of different therapies for HIV infection and for opportunistic pathogens. SHARE and MACS have just completed the recruitment of 1326 additional participants, including 352 in SHARE, who are younger and more non-Caucasian than the cohort previously recruited. This application requests the continuation of the followup of the SHARE cohort from 2004 to 2008. Expected survival and continuation in the study of HIV-infected cohort members through this time period is 88%. Specific Aims of the renewal include: determine the long-term effectiveness of highly active antiretroviral therapy (HAART); define determinants of individual responses to HAART including host genetic characteristics, co-infections (hepatitis viruses, HHV-8), immune responses to HIV, adherence, race/ethnicity; define mechanisms of host resistance to HIV infection and progression of the infection; and serve as a platform for independently funded pathogenesis studies and other collaborative research, including virological and immunological mechanisms of HIV-1 pathogenesis, laboratory correlates of disease progression or non-progression, and biological interactions between co-infections and HIV. These aims can be addressed only with continued followup of this extremely well-characterized cohort. SHARE and the MACS should continue to play a leading role in studies designed to lead to better treatments and preventive vaccines for HIV infection.

描述(由申请人提供)： 这项旨在帮助艾滋病研究工作的研究(SHARE)是由NIAID和NCI于1983年资助的，目的是研究人类免疫缺陷病毒1型(HIV)感染的自然历史。Share与芝加哥、匹兹堡和洛杉矶的类似网站一起组成了多中心艾滋病队列研究(MACS)。MACS参与者，包括1447名登记参加SHARE的人，自1984年以来每半年被跟踪一次，并提供了问卷数据、体检数据、实验室数据(包括艾滋病毒血清和T细胞亚群测量)以及大量血浆、血清、冷冻保存的外周血单核细胞和其他标本。评估和跟踪SHARE和MACS中艾滋病毒感染的流行和事件病例，为以下方面提供了关键的见解：艾滋病毒-1感染的风险因素、艾滋病毒感染一旦确立、艾滋病毒感染的宿主防御、影响艾滋病毒发病的遗传因素、以及针对艾滋病毒感染和机会性病原体的不同治疗方法的使用和疗效。Share和Mac刚刚完成了1326名额外参与者的招募，其中包括352名Share，他们比之前招募的队列更年轻，更不是高加索人。这项申请要求从2004年至2008年继续对共享队列进行后续行动。在这段时间内，艾滋病毒感染队列成员在研究中的预期存活率和持续存活率为88%。更新的具体目的包括：确定高效抗逆转录病毒疗法(HAART)的长期有效性；确定HAART个人反应的决定因素，包括宿主遗传特征、合并感染(肝炎病毒，HHV-8)、对艾滋病毒的免疫反应、依从性、种族/族裔；确定宿主对艾滋病毒感染的抵抗和感染进展的机制；并作为独立资助的病因学研究和其他合作研究的平台，包括艾滋病毒-1致病机理的病毒学和免疫学机制、疾病进展或不进展的实验室相关性，以及联合感染与艾滋病毒之间的生物相互作用。只有通过对这一极具特点的群体继续采取后续行动，才能实现这些目标。SHARE和互委会应继续在旨在为艾滋病毒感染提供更好的治疗和预防性疫苗的研究中发挥主导作用。